Recce Pharmaceuticals Receives Ethics Approval to Start
Phase I Intravenous Clinical Trial of RECCE® 327
Highlights:
• Phase I clinical trial of RECCE® 327 approved to start intravenous ascendingdose, randomized, placebo-controlled, parallel, double-blind, single-dose
• According to Pew Charitable Trusts, R327 is the only clinical stage antibiotic
for the indication of sepsis - largest unmet medical need in human health
• First patient dosing December 2021 at Adelaide’s CMAX clinical trial facility
Ann: Ethics Approval to Start Phase 1 Intravenous Clinical Trial, page-4
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
44.5¢ |
Change
0.080(21.9%) |
Mkt cap ! $128.6M | |||
| Open | High | Low | Value | Volume |
| 37.5¢ | 44.5¢ | 37.5¢ | $191.2K | 477.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 12222 | 44.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 45.0¢ | 10976 | 2 |
View Market Depth
| Last trade - 16.10pm 25/07/2025 (20 minute delay) ? |
| RCE (ASX) Chart |